¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Poisoning by agents primarily affecting the gastrointestinal system"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • superficial musculo-aponeurotic system platysma flap
    ¾ó±¼³ÎÈûÁÙ°èÅë³ÐÀº¸ñ±ÙÆÇ, Ç¥Àç±Ù°Ç¸·°èÅëȰ°æ±ÙÆÇ
  • system
    1. °èÅë, °è, ü°è 2. ÀåÄ¡ 3. Á¦µµ, ¹ý 4. ºÐ·ù¹ý
  • system analysis
    °èÅëºÐ¼®
  • self-system
    ÀÚ±âü°è
  • skeletal system
    »À´ë°èÅë, °ñ°Ý°è
  • social security system
    »çȸº¸ÀåÁ¦µµ
  • urinary system
    ºñ´¢°èÅë, ºñ´¢°è
  • urogenital system
    ºñ´¢»ý½Ä±â°èÅë, ºñ´¢»ý½Ä±â°è
  • vascular system
    Ç÷°ü°èÅë, Ç÷°ü°è
  • vegetative nervous system
    ½Ä¹°½Å°æ°èÅë, ½Ä¹°½Å°æ°è
  • value system
    °¡Ä¡Ã¼°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • Rh blood group system
    ¾Ë¿¡ÃëÇ÷¾×Çü±º
  • self-system
    ÀÚ±âü°è
  • system
    °èÅë, ÀåÄ¡, Á¦µµ
  • scavenging system
    ¸¶Ãë°¡½ºÁ¦°Åü°è
  • skeletal system
    »À´ë°èÅë
  • social security system
    »çȸº¸ÀåÁ¦µµ
  • somatosensory system
    ¸ö°¨°¢°èÅë
  • sound conduction system
    ¼Ò¸®Àü´Þ°èÅë, ÀüÀ½°è
  • static system
    Á¤Áö°è
  • stereotactic system
    Á¤À§°íÁ¤±â
  • subcortical descending system
    °ÑÁú¹ØÇÏÇà°è, °ÑÁú¹Ø³»¸²°èÅë
  • superficial musculo-aponeurotic system
    ¾ó±¼³ÎÈûÁÙ°èÅë
  • to and fro absorbent system
    ¿Õº¹Èí¼ö½Äȸ·Î
  • transdermal drug delivery system
    °æÇǾ๰Àü´Þü°è
  • urinary system
    ºñ´¢°èÅë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • genitourinary system
    ºñ´¢»ý½Ä±â°èÅë(ù²èñßæãÖÐïͧ÷Ö).
  • glial cell of central nervous system
    ÁßÃ߾Ʊ³¼¼Æ÷
  • glial cell of peripheral nervous system
    ¸»ÃʾƱ³¼¼Æ÷
  • global budget system
    ÃѾ׿¹»êÁ¦, ÃѾװè¾àÁ¦.
  • guarantee system
    º¸ÁõÁ¦µµ(ËÓ̡̡̬).
  • h2o2-myeloperxidase-halide system
    °ú»êÈ­¼ö¼Ò-°ñ¼ö°ú»êÈ­È¿¼Ò-ÇÒ·Î°Õ °èÅë
  • hamatopoietic system
    Á¶Ç÷±â°ü(ðãúìÐïί)
  • health care delivery system
    ÀÇ·áÀü´ÞÁ¦µµ(ËöËíËøËÀ̡̬).
  • health care system
    º¸°ÇÀÇ·áü°è.
  • health information system
    º¸°ÇÁ¤º¸Ã¼°è.
  • heterogeneous system
    ºÒ±ÕÀϰè, ºÒ±ÕÁú°è.
  • hexagonal system
    À°¹æ°áÁ¤°è.
  • homogeneous system
    ±ÕÁú°è, ±ÕÀϰè.
  • hospital information system
    º´¿øÁ¤º¸Ã¼°è.
  • hydrophilic system
    Ä£¼ö°è(öÑâ©Í§).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • metallic poisoning
    ±Ý¼ÓÁßµ¶(¡­ñéÔ¸).
  • mushroom poisoning
    ¹ö¼¸Áßµ¶(ÊÙÌ¡ËÄ).
  • mushroom poisoning
    ¹ö¼¸Áßµ¶(¡­ñéÔ¸)
  • mushroom poisoning ³ª
    ¹ö¼¸Áßµ¶(¡­ñéÔ¸).
  • opiate poisoning
    ¾ÆÆíÁßµ¶(ä¹ø¸ñéÔ¸).
  • organophosphate poisoning
    À¯±âÀλ꿰Áßµ¶
  • oxygen intoxication =o. poisoning
    »ê¼ÒÁßµ¶(¡­ñéÔ¸).
  • oxygen poisoning
    »ê¼ÒÁßµ¶(Áõ)(¡­ñéÔ¸ñø).
  • paraquat poisoning
    ÆÄ¶óÄâÆ® Áßµ¶Áõ
  • pesticide poisoning
    »ìÃæÁ¦Áßµ¶(߯õùð¥ñéÔ¸)
  • plumbism =lead poisoning
    ³³Áßµ¶(ÊÙÌ¡ËÄ).
  • plumbism =lead poisoning
    ³³Áßµ¶(¡­ñéÔ¸)
  • plumbism =lead poisoning
    ³³Áßµ¶(¡­ñéÔ¸).
  • poisoning
    Áßµ¶(Ì¡ËÄ), Áßµ¶»óÅÂ(Ì¡ËÄË×̬).
  • poisoning
    Áßµ¶(ñéÔ¸), Áßµ¶»óÅÂ(ñéÔ¸ßÒ÷¾).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
MEOS Microsomal Ethanol Oxidizing System
  = MFOS; Mixed Function Oxidase System
TNM staging System standard Tumor, NOde & Metastasis staging system
ARMS adverse reaction monitoring system; amplification refractory mutation system
CSD carotid sinus denervation; cat scratch disease; combined system disease; conditionally streptomycin ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
DSS Decision Support System
EMS Emergency Medical System
ENS Enteric Nervous System
ES Expert System
FARS Fatal Accident Reporting System
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • occlusal system
    ÀÇÄ¡ ÀΰøÄ¡ ±³ÇÕ¸é ¹è¿­ ü°è
    ÀÇÄ¡¿¡¼­ ÀüÄ¡¿Í ±¸Ä¡ÀÇ °¢ Ä¡¾ÆÀÇ Çüųª µðÀÚÀÎ, ÀüüÀû ¹è¿­ µî.
  • oil immersion system
    À¯Ä§ ÀåÄ¡
  • open vessel system
    °³¹æ ¼øÈ¯°è
  • opiate sensitive system
    ¾ÆÆí¼º °¨¼º°è
  • opioid-mediated analgesia system
    ¾ÆÆí ¸Å°³ ÁøÅë°è
  • osseous system
    »À ±â°ü, °ñ°è
  • oxidation reduction system
    »êÈ­ ȯ¿ø°è
  • pain system
    µ¿Åë°è
  • pain transmission system
    µ¿Åë Àü´Þ°è
  • pain-modulating system
    µ¿Åë Á¶Àý°è
    ÁßÃß ½Å°æ°è´Â Åë°¢À» Àü´ÞÇÏ¿© ÅëÁõÀ» ´À³¢°Ô ÇÏ´Â ±â´É À̿ܿ¡µµ µ¿ÅëÀ» ÅëÁ¦ÇÏ´Â ÀÏ·ÃÀÇ ½Å°æ Á¶Á÷À» °®°í ÀÖÀ¸¸ç, ½Å°æ ¼¼Æ÷¿¡¼­ o
  • pallidal system
    ´ãⱸ°è
  • palm and sole system of identification
    ¼öÀå Á·Àú È®Àιý
  • peripheral nervous system
    ¸»ÃÊ ½Å°æ°è
    1. ³ú ½Å°æ, ô¼ö ½Å°æ, ÀÚÀ² ½Å°æ. 2. ³ú¿Í ô¼ö ¹Ù±ù¿¡ ÀÖ´Â ¿îµ¿ ¹× °¨°¢ÀÇ ±³°¨½Å°æ°ú ºÎ±³°¨½Å°æ.
  • peripheral pain sensory system
    ¸»Ãʼº Åë°¢°è
  • peripheral vascular system
    ¸»ÃÊÇ÷°ü°è
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
carbohydrates and hypoglycaemic agents A collective term for carbohydrates and agents used to lower the level of glucose in the blood.
(12 Dec 1998)
cardiovascular agents Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
(12 Dec 1998)
gaba agents Substances used for their pharmacological actions on gabaergic systems. Gabaergic agents include agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function.
(12 Dec 1998)
radiation-protective agents Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other, e.g. Military, purposes.
(12 Dec 1998)
radiation-sensitizing agents Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.
(12 Dec 1998)
vasoconstrictor agents Drugs used to cause constriction of the blood vessels.
(12 Dec 1998)
vasodilator agents Drugs used to cause dilation of the blood vessels.
(12 Dec 1998)
reducing agents Materials that add an electron to an element or compound, that is, decrease the positiveness of its valence.
(12 Dec 1998)
renal agents Drugs used for their effects on the kidneys' regulation of body fluid composition and volume. The most commonly used are the diuretics. Also included are drugs used for their antidiuretic and uricosuric actions, for their effects on the kidneys' clearance of other drugs, and for diagnosis of renal function.
(12 Dec 1998)
reproductive control agents Substances used either in the prevention or facilitation of pregnancy.
(12 Dec 1998)
glycine agents Substances used for their pharmacological actions on glycinergic systems. Glycinergic agents include agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function.
(12 Dec 1998)
menstruation-inducing agents Chemical compounds that induce menstruation either through direct action on the reproductive organs or through indirect action by relieving another condition of which amenorrhoea is a secondary result.
(12 Dec 1998)
chelating agents Organic chemicals that form two or more coordination bonds with a central metal ion. Heterocyclic rings are formed with the central metal atom as part of the ring. Some biological systems form metal chelates, e.g., the iron-binding porphyrin group of haemoglobin and the magnesium-binding chlorophyll of plants. They are used chemically to remove ions from solutions, medicinally against microorganisms, to treat metal poisoning, and in chemotherapy protocols.
(12 Dec 1998)
chemical warfare agents Chemicals that are used to cause the disturbance, disease, or death of humans during war.
(12 Dec 1998)
riot control agents, chemical Chemical substances which are employed during a riot in order to control or disperse the rioting parties.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á